Previous 10 | Next 10 |
iBio (IBIO) has risen more than fourfold in value over the past six-month period amid COVID-19 vaccine hopes. That has not discouraged Cantor Fitzgerald to initiate the stock’s coverage with an overweight rating with a price target of $3, more than double the previous close. The shares...
Gainers: Adamis Pharmaceuticals (ADMP) +47%, AzurRx BioPharma (AZRX) +38%, 111 (YI) +27%, Obalon Therapeutics (OBLN) +17%, iBio (IBIO) +17%.Losers: Celsion CLSN -18%, ViewRay VRAY -14%, ADiTx Therapeutics (ADTX) -14%, Passage Bio PASG ...
Adamis Pharmaceuticals (ADMP) +66% as its epinephrine products added to Walgreens club.Climate Change Crisis Real Impact I Acquisition Corporation (CLII) +48% as EV fast charging company EVgo to go public via SPAC.SCYNEXIS (SCYX) +36%.Humanigen (HGEN) +20% on expanding partners...
Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a patent for a 3D holograp...
Israel has already immunized about 647,000 people against COVID-19, a whopping 7% of its more than 9.2M residents, according to the Israeli Ministry of Health. In fact, the country has vaccinated more people in the first nine days of its campaign than its total coronavirus infections, which c...
iBio (IBIO) appointed Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer, effective Jan. 18, 2020."Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to as...
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Off...
"We don't know at the moment if our vaccine is also able to provide protection against this new variant," but because the proteins on the variant are 99% the same as the prevailing strains, BioNTech (BNTX) has "scientific confidence” in the vaccine."The likelihood that our vaccine work...
BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten public offering of approximately 29.7 million...
On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS) , iBio (NYSEMKT: IBIO) , and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively. One common catalyst seems to be the secondary-share issues anno...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...